Frankfurt
11.11.26 | 08:05
58,00 Euro
-0,85 % -0,50
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 58,50 | 60,50 | 10:23 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 6 | GlobeNewswire (USA) | ||
| Do | Novonesis Q3 Profit Advances | 399 | AFX News | BRUSSELS (dpa-AFX) - Novonesis (NVZMF.PK) released earnings for its third quarter that Increases, from the same period last yearThe company's bottom line came in at EUR187.9 million, or EUR0.40... ► Artikel lesen | |
| Do | Novonesis (Novozymes A/S): 9M 2026: Novonesis delivered 7% organic sales growth, confirming full-year outlook | 447 | GlobeNewswire (Europe) | COPENHAGEN, Denmark - November 5, 2026. Novonesis delivered strong Q3 sales leading to 9M financial results at 7% organic sales growth and adjusted EBITDA margin of 37.9%. In addition, our 2026 outlook... ► Artikel lesen | |
| 02.11. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 4 | GlobeNewswire (USA) | ||
| 26.10. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 4 | GlobeNewswire (USA) | ||
| 26.10. | Novonesis (Novozymes A/S): Major shareholder announcement | 7 | GlobeNewswire (USA) | ||
| 19.10. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 14 | GlobeNewswire (USA) | ||
| 15.10. | Novonesis Opens Doors to Students to Inspire the Next Generation of U.S. Biomanufacturing Talent | 4 | GlobeNewswire (USA) | ||
| NOVONESIS A/S ADR Aktie jetzt für 0€ handeln | |||||
| 12.10. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 2 | GlobeNewswire (USA) | ||
| 05.10. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 8 | GlobeNewswire (USA) | ||
| 01.10. | Novonesis Expands Dairy Cultures Capacity Amid Rising Demand | 3 | ESM Magazine | ||
| 01.10. | Novonesis (Novozymes A/S): Novonesis completes acquisition of MicroBioGen, strengthening its yeast capabilities | 744 | GlobeNewswire (Europe) | Novonesis completes acquisition of MicroBioGen, strengthening its yeast capabilities The acquisition adds advanced yeast-breeding expertise with a proven track record in bioethanol and broader potential... ► Artikel lesen | |
| 28.09. | Novonesis celebrates major expansion of West Allis production facility, strengthening North American dairy innovation and manufacturing | 546 | GlobeNewswire (Europe) | WEST ALLIS, Wis., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Novonesis, a global leader in biosolutions, announced the completion of a major expansion at its West Allis, Wisconsin production facility. The... ► Artikel lesen | |
| 28.09. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 2 | GlobeNewswire (USA) | ||
| 21.09. | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | 8 | GlobeNewswire (USA) | ||
| 14.09. | Novonesis (Novozymes A/S): Initiation of Novonesis' share buyback program | 13 | GlobeNewswire (USA) | ||
| 02.09. | Novonesis (Novozymes A/S): Novonesis to build next generation enzyme production facility in India | 709 | GlobeNewswire (Europe) | Novonesis will invest €600 million to expand its site in?Patalganga?and build?a state-of-the-art?facility. This marks another step in the company's long-term growth strategy and continued investment... ► Artikel lesen | |
| 26.08. | Novonesis Expands U.S. Workforce Development Efforts to Build the Next Generation of Biomanufacturing Talent | 8 | GlobeNewswire (USA) | ||
| 25.08. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 5 | GlobeNewswire (USA) | ||
| 24.08. | Johnson & Johnson, Novozymes und mehr Dividenden im global market - Ex-Tag 25.08.2026 | 10 | Wiener Börse |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GENMAB | 469,30 | -2,72 % | Genmab Profit Drops In Q3, Maintains FY26 Revenue Outlook | BRUSSELS (dpa-AFX) - Thursday, Genmab A/S (GMAB) announced its financial results for the third quarter, reporting a net profit of $342 million, or $5.581 a share, compared with $401 million... ► Artikel lesen | |
| INSMED | 107,32 | +0,15 % | H.C. Wainwright initiates Insmed stock coverage with buy rating | ||
| PEPGEN | 4,620 | +0,22 % | PepGen soars on promising early data for muscular dystrophy drug | ||
| PRAXIS PRECISION MEDICINES | 337,27 | -0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DISC MEDICINE | 84,77 | +0,15 % | Disc Medicine auf der Guggenheim-Konferenz: Finanzstarker Vorstoß in die Vermarktungsphase | ||
| ARCUTIS BIOTHERAPEUTICS | 27,385 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 17,920 | 0,00 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 15,480 | 0,00 % | Tango Therapeutics, Inc.; Erasca, Inc.: Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 | ||
| EDGEWISE THERAPEUTICS | 46,570 | +0,09 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,600 | -0,13 % | Cogent Biosciences auf Guggenheim-Konferenz: Marktstart rückt näher | ||
| TANGO THERAPEUTICS | 24,280 | -0,08 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| ABSCI | 9,970 | 0,00 % | Absci auf der Guggenheim-Gesundheitskonferenz: Eigene Pipeline rückt in den Fokus | ||
| KYMERA THERAPEUTICS | 136,60 | -0,03 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,160 | +0,04 % | Jones Trading initiates Beam Therapeutics stock coverage with buy rating | ||
| ENLIVEN THERAPEUTICS | 51,29 | +0,18 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen |
NOVONESIS A/S ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,50 (-0,85 %) liegt der Kurs bei 58,00 Euro. Die Dividendendrendite beträgt aktuell 0,00 % (berechnet anhand der Ausschüttung von 0,00 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NOVONESIS A/S ADR finden Sie auf Wallstreet Online.